Lightning-Nl
Bluelighter
- Joined
- Nov 11, 2012
- Messages
- 1,245
I finally came across an explanation as to why but benzodiazepines can be so psychologically addicting to some people. These studies explained the what/when/how and why of the GABA subtypes and interactions.
Simply put, Benzodiazepines causes a massive disinhibition of Dopamine regulation through binding at the alpha-1 subtype of GABA-a. Even more selective agonists (or PAM agent in this case) could, theoretically explain the adverse side-effects and addiction potential of Zolpidem. Zolpidems highly selective to alpha-1 and likely facilitates over-active expressive repression dipression exertion upon dopaminergic activity. Massive dopamine activity would explain Zolpidems hallucinations and sleep walking. I've always wondered with the amine group of the nitrogen and three carbons on the Zolpidem molecule if it has nAChR or other cholinergic activity.
Anyways, why is all of this? Well here's an excerpt from the study.
Now here's where things get even more interesting. After the findings of the study above we're released, another doctor decided to perform tests on the interaction between benzodiazepines and the alpha-1 subtype of GABAA. These finding found that increased alpha-1 activity caused a massive migration in AMPA receptors located on DA neurons. The expressed AMPA receptors are excitatory to glutamate, and won't actually cause any increase in dopaminergic activity, but will actually cause excitatory repression of synapse cleft surges in dopamine activity effectively suppressing dopamine activity.
I'm looking for a study I once saw on this right this minute, but can't find it at the moment. Will update in a moment.
It appears that while glutamate and monoamine neurotransmitters are both excitatory, monoamines suppress glutamate activity in the mesocorticolimbic reward pathways, and glutamate suppresses monoamine activity in general around the nervous system. Benzodiazepines through GABAergic neurotransmission, suppress glutamatergic activity via calcified ion channel openings and negatively charged chloride ion pathways negating suppression of monoamines. Effectively causing spikes in dopamine activity due to lack of suppression of neurotransmission of glutamate. or "spikes" in monoaminergic activity.
I've yet to see a study on it but my theory is that through nAChR receptor channel activity, chloride ion and calcium ion channel manipulation and other bindings release opioid peptides and causes neurotransmission of dopamine. Speculation I can provide is that some of the antinociceptive activity of benzodiazepines caused by smooth muscle relaxation is the depressing of the muscle due to neuromusclar sedation.
Studies
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3013137/pdf/pone.0015870.pdf
doi:10.1038/463743a
http://www.drugabuse.gov/news-event...nderlies-benzodiazepines-addictive-properties
Simply put, Benzodiazepines causes a massive disinhibition of Dopamine regulation through binding at the alpha-1 subtype of GABA-a. Even more selective agonists (or PAM agent in this case) could, theoretically explain the adverse side-effects and addiction potential of Zolpidem. Zolpidems highly selective to alpha-1 and likely facilitates over-active expressive repression dipression exertion upon dopaminergic activity. Massive dopamine activity would explain Zolpidems hallucinations and sleep walking. I've always wondered with the amine group of the nitrogen and three carbons on the Zolpidem molecule if it has nAChR or other cholinergic activity.
Anyways, why is all of this? Well here's an excerpt from the study.
Mechanisms of Benzodiazepine Addiction (Left Image) Both inhibitory interneurons (labeled GABA) and dopaminergic neurons (labeled DA) are subject to the restraining influence of the inhibitory neurotransmitter GABA. A key difference, however, is that GABA influences the inhibitory interneurons largely via the alpha-1 subset of GABAA receptors and the dopaminergic neurons largely via the alpha-3 subtype. (Right Image) Benzodiazepines currently on the market do not interact strongly with alpha-3 GABAA receptors on dopaminergic neurons and so have no direct impact on dopamine release. However, the drugs do interact strongly with alpha-1 GABAA receptors, thereby curtailing inhibitory interneurons’ release of GABA into synapses with dopaminergic neurons. The net result is a lessening of GABA restraint on the dopaminergic neurons and an increase in dopamine release.
To prove that activation of alpha-1 GABAA receptors underlies benzodiazepines’ dopamine effect, the researchers administered a typical benzodiazepine, midazolam, to two groups of mice. The results supported the researchers’ proposed mechanism: In normal animals, the firing rate of interneurons decreased in response to the drug, while that of dopamine-producing neurons increased. In contrast, in animals that were genetically altered to prevent benzodiazepines from potentiating alpha-1 GABAA receptors, the drug had little or no impact on neuron firing.
Now here's where things get even more interesting. After the findings of the study above we're released, another doctor decided to perform tests on the interaction between benzodiazepines and the alpha-1 subtype of GABAA. These finding found that increased alpha-1 activity caused a massive migration in AMPA receptors located on DA neurons. The expressed AMPA receptors are excitatory to glutamate, and won't actually cause any increase in dopaminergic activity, but will actually cause excitatory repression of synapse cleft surges in dopamine activity effectively suppressing dopamine activity.
Dr. Lüscher and colleagues showed that benzodiazepines induce AMPA receptor migration via the alpha-1 GABAA receptors. In these experiments, brain tissue from normal mice exhibited GluA2-lacking AMPA receptors after a single injection of midazolam, but tissue from mice with benzodiazepine-insensitive alpha-1 GABAA receptors did not. Recordings of intracellular electrical currents confirmed synaptic changes of dopamine-producing neurons in the normal mice and not the altered mice. To pin down the relationship further, the researchers injected mice with two other compounds, one (zolpidem) that preferentially activates only the alpha-1 GABAA receptors, and one (L-838417) that antagonizes these receptors. GluA2-lacking AMPA receptors were expressed in dopamine-producing neurons following a treatment with zolpidem, but not with L-838417.
I'm looking for a study I once saw on this right this minute, but can't find it at the moment. Will update in a moment.
It appears that while glutamate and monoamine neurotransmitters are both excitatory, monoamines suppress glutamate activity in the mesocorticolimbic reward pathways, and glutamate suppresses monoamine activity in general around the nervous system. Benzodiazepines through GABAergic neurotransmission, suppress glutamatergic activity via calcified ion channel openings and negatively charged chloride ion pathways negating suppression of monoamines. Effectively causing spikes in dopamine activity due to lack of suppression of neurotransmission of glutamate. or "spikes" in monoaminergic activity.
I've yet to see a study on it but my theory is that through nAChR receptor channel activity, chloride ion and calcium ion channel manipulation and other bindings release opioid peptides and causes neurotransmission of dopamine. Speculation I can provide is that some of the antinociceptive activity of benzodiazepines caused by smooth muscle relaxation is the depressing of the muscle due to neuromusclar sedation.
Studies
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3013137/pdf/pone.0015870.pdf
doi:10.1038/463743a
http://www.drugabuse.gov/news-event...nderlies-benzodiazepines-addictive-properties
Last edited: